Abstract To develop new anticancer agents has been considered as a useful and necessary strategy to suppress highly-metastatic lung cancer, the leading cause of cancer-related deaths in the world. In this study, we synthesized a new compound ethyl 6-bromocoumarin-3-carboxylyl L-theanine (TBrC) and studied the anticancer activity of TBrC and its molecular mechanisms of action. Our results show that TBrC remarkably inhibits the proliferation and migration in highly-metastatic lung cancer cells by inducing apoptosis and cell cycle arrest as well as regulating related protein expressions. Further study indicated that TBrC not only enhances the protein levels of Bax, cytosolic cytochrome c, caspase-3 and PARP-1 but also reduces the protein expressions of Bcl-2, cyclin D1, VEGFR1 and NF-jB as well as inhibits the phosphorylation and expressions of VEG-FR2 and Akt in the cancer cells. More importantly, TBrC displays strong suppression of highly-metastatic tumor growth and reduces the tumor weight by 61.6 % in tumor-bearing mice without toxicity to the mice. Our results suggest that TBrC suppresses the proliferation and migration of lung cancer cells via VEGFRAkt-NF-jB signaling pathways; TBrC may have a wide therapeutic and/or adjuvant therapeutic application in the treatment of lung cancer.
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Introduction
It is estimated that there are more than 226,000 new cases and about 160,000 deaths from Lung and bronchus cancer in the U.S. in 2012 (Siegel et al. 2012) . Lung adenocarcinoma has become the leading cause of cancer-related deaths in the world (Jemal et al. 2008 Siegel et al. 2011 Siegel et al. , 2012 . Despite recent advances in diagnosis and treatment, overall 5-years survival of lung cancer patients is only about 15 %. The patients with advanced disease have a median survival of approximately 10 months when treated with standard platinum-based therapy. Hence, there is an imminent need for better therapies and/or anticancer agents for lung cancer. Theanine (cglutamylethylamide) is a characteristic amino acid in tea and has been widely used as a safe food additive without limitation to its dose. The anticancer activities of theanine against some cancers have been reported (Sugiyama and Sadzuka 1998; Sugiyama et al. 1999) . Our previous study indicated that theanine and the sera from theanine-fed rats inhibited the invasion of rat hepatoma cells in vitro and ex vivo (Zhang et al. 2001) and hepatoma growth in vivo (Zhang et al. 2002) . In order to further enhance the anticancer activity of theanine and develop a new anticancer agent targeting lung cancer, we have synthesized a new compound TBrC based on the structure of theanine and investigated the effects of TBrC on induction of apoptosis and cell cycle arrest, migration, and tumor growth as well as the related receptors-mediated signaling pathways in highly-metastatic lung cancer cells.
Materials and methods

Chemicals
Fibronectin and Boyden chambers were purchased from BD Inc. (BD Biosciences, San Jose, CA, USA) and Corning Inc. (Corning, NY, USA), respectively. DMEM, penicillin, streptomycin, fetal bovine serum (FBS), trypsin/EDTA, propidium iodide, Ly294002 (Ly), Bay 11-7082 (Bay), 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), collagenase, and all other chemicals including materials for the synthesis of TBrC were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Preparation of ethyl 6-bromocoumarin-3-carboxylyl L-theanine (TBrC) All materials we used were purchased from commercial suppliers (Sigma Chemical Co.) and used without further purification. Solvents were distilled prior to use and flash chromatography was performed using silica gel (60 Å , 200-300 mesh). 6-bromo-2-oxo-2H-chromene-3-carboxylic acid (BrC) was obtained according to the literature method (Deshmukh et al. 2003) . All reactions were monitored by thin-layer chromatography on 0.25 mm silica gel plates (60GF-254) and visualized with UV light, or Ninhydrin Spray (0.5 % in butanol). Melting points were determined on an electrothermal melting point apparatus.
1 H, 13 C NMR spectra were determined on a Brucker Avance 500/125 spectrometer using TMS as an internal standard in DMSO-d 6 (Hexadeuterodimethyl sulfoxide) or CDCl 3 (Chloroform-d) solutions. Chemical shifts are reported in delta (d) units, parts per million (ppm) downfield from trimethylsilane. ESI-MS were determined on an API 4000 spectrometer (AB SCIEX, Concord, Ontario, Canada).
The scheme of chemical synthesis of TBrC is shown in the Fig. 1 . The targeted compound TBrC was synthesized as follows. To a solution of L-Theanine 87 mg (500 microM) in absolute ethanol (1 mL), SOCl 2 0.055 ml (760 microM) was added slowly, and the mixture was stirred at room temperature for 2 h, then the resulting mixture was concentrated under reduced pressure to give ethyl L-theanine (ET). To the obtained oily residue ET, CH 2 Cl 2 (20 mL) was added, then 6-bromo-2-oxo-2H-chromene-3-carboxylic acid (BrC) (224 mg, 1,000 microM), 1.07 ml DIPEA (N,NDiisopropylethylamine) (791.8 mg; 610 microM) and 383 mg EDCI (1-ethyl-3-[3-(dimethylamino) propyl] carbodiimide) (200 microM) were added, respectively. The mixture was stirred at room temperature for 1 h, and then was concentrated under reduced pressure to remove the solvent. The crude product was purified by chromatography (acetone/petroleum ether = 1/5) on silica gel to give a light yellow solid (Yield = 84.6 %; purity of 98 %). m. Cell culture and in vitro proliferation assay
In order to obtain normal primary human umbilical vein endothelial cells (HUVECs), we recruited mothers who assented and gave written consent to contributing 20 cm of umbilical cord postpartum. HUVECs were isolated according to a previous reported method (Jaffe et al. 1973 ) with minor modifications. Briefly, untraumatized umbilical cord segments were cannulated and perfused with 200-400 mL phosphate buffered saline (PBS) to remove all traces of blood. Then the vein lumen was filled with PBS containing 1 mg/mL collagenase and incubated at 37°C for 10 min. The contents of the vein were gently flushed with an equal volume of PBS, centrifuged at 1,000 r/min for 10 min and re-suspended in DMEM medium supplemented with 10 % heat-inactivated FBS. After 12 h, fresh medium was added. The cells were grown in DMEM supplemented with 10 % heat-inactivated FBS, glutamine (2,000 microM), penicillin (100 units/ mL), and streptomycin (100 lg/mL). The cultures were maintained at 37°C in a humidified atmosphere of 95 % air/5 % CO 2 . Culture medium was refreshed every 2 days. After 6-8 days, uniform monolayers developed in the primary cultures and 0.25 % trypsin was used to harvest cells. Immunohistochemical staining for CD34 was employed to identify the specificity of endothelial cells. The HUVECs were used for in vitro proliferation assay described below. The highly-metastatic Lewis lung cancer (LLC) cell line was obtained from the American Type Culture Collection. The cell line of LLC was cultured in DMEM containing 10 % heat-inactivated FBS, glutamine (2,000 microM), penicillin (100 U/ml) and streptomycin (100 lg/ml) at 37°C in a humidified incubator with 95 % air /5 % CO 2 atmosphere. The in vitro proliferation assay was performed according to our published methods Luan et al. 2010; Zhang et al. 2000; Jiang et al. 2010) . LLC cells and HUVECs were, respectively, plated in 96-well plates (Becton-Dickinson, Franklin Lakes, NJ, USA) at 2 9 10 3 (in the case of LLC cells) or 5 9 10 3 (in the case of HUVECs) per well and incubated overnight to allow attachment. The cells in the control group were treated with DMSO [0.1 % (v/v) Each experiment was performed in triplicate and repeated at least three times.
Flow cytometry for cell cycle analysis and apoptosis
These were done according to our published methods (Wang et al. 2009; Yu et al. 2009; Zhang et al. 2000 Zhang et al. , 2012a . In brief, LLC cells were treated for 48 h with TBrC ( . Twenty-thousand events were analyzed per sample and the cell cycle distribution and apoptosis were determined based on DNA content and the Sub-G 1 cell population, respectively.
In vitro migration assay
Tumor cell migration was measured by examining cell migration through fibronectin-coated polycarbonate filters, using modified transwell chambers. In brief, LLC cells (5 9 10 4 ) were seeded onto the upper chamber in 200 lL of serum-free medium containing different concentrations of TBrC (4-16 microM) or theanine (4-16 microM); the lower compartment was filled with 0.66 mL of DMEM medium supplemented with 10 % of FBS (as a chemoattractant). The cells in the control group were treated with DMSO (0.1 %, final concentration). After incubation for 6 h at 37°C, the cells that migrated to the lower surface of the filter were fixed and stained using propidium iodide. The cells on the upper side of the filter were removed using a rubber scraper. The migrated cells on the underside of the filter were counted and recorded for images under a fluorescent microscope (Nikon, TE2000-U, Tokyo, Japan). Experiments were performed in triplicate.
Western blot analysis
This was performed according to our published methods with some modifications (Wang et al. 2009; Yu et al. 2009; Zhang et al. 2009 , Jiang et al. 2010 Zhang et al. 2012a ). In brief, LLC cells were treated with different concentrations of TBrC (16-250 microM), theanine (16-250 microM), Ly294002 (Ly, 16 microM), or Bay (3.2 microM). The cells in the control group were treated with DMSO [0.1 % (v/v), final concentration]. The treated cells were collected either at 30 min for detection of phosphorylation ratios of pVEGFR2/VEGFR2 and pAkt/Akt, or at 48 h for detection of protein expressions of Bcl-2, Bax, procaspase/caspase-3, PARP-1, cyclin D1, VEGFR1, NF-jB (p65), and cytosolic cytochrome c. The cells were harvested and washed with PBS. Whole cellular proteins were extracted and cytosolic fractions were prepared following the procedure described by the manufacturer (Beyotime, Haimen City, China). The protein concentration of the extracts was determined using the Bradford method. Equal amounts of cell extracts were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed with the primary antibodies to the detected proteins mentioned above, and then horseradish peroxidase-conjugated secondary antibodies, respectively. Anti-b-actin antibody was used as a loading control. The primary and secondary antibodies were used as follows: The primary anti-p-Akt (Ser473) rabbit mAb, anti-Akt rabbit mAb, anti-NF-jB (p-65) rabbit mAb, anti-p-VEGFR2 (Tyr1175) rabbit mAb, anti-VEGFR2 rabbit mAb, anti-VEGFR1 rabbit polyclonal antibody and the anti-rabbit IgG, HRP-conjugated antibody were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA). The primary anti-Bcl-2 rabbit polyclonal antibody, anti-caspase-3 rabbit polyclonal antibody, anti-cyclin D1 rabbit polyclonal antibody, anti-PARP-1 mouse mAb, anti-cytochrome c mouse mAb, anti-b-actin mouse mAb and the anti-rabbit IgG, HRP-conjugated antibodies and anti-mouse IgG, HRP-conjugated antibody were purchased from Santa Cruz Technology Inc. (Shanghai, China). Detection was done using an enhanced chemiluminescence system (GE Healthcare Life Sciences, Piscataway, NJ USA).
Subcutaneous tumor model C57/BL6 mice (age range, 6 weeks) were purchased from the Tumor Research Institute (Chinese Academy of Sciences, Beijing, China). All animal procedures were carried out in accordance with the guidelines established by the Animal Care and Use Committee (ACUC) at the Yantai University and were approved by the ACUC at the Yantai University, China. Single-cell suspensions containing 0.6 9 10 6 LLC cells in 0.1 mL Hank's balanced salt solution were injected s.c. into the rear left flank of each mouse. About 2 weeks after administration, 120-150 mm 3 tumors appeared in all the mice. At this time, mice were randomized into four groups (six mice pre group): (1) Control group (vehicle); (2) Cisplatin group (1.5 mg/kg/day); (3) Theanine group (theanine 50 mg/kg/day); (4) TBrC group (TBrC 50 mg/kg/day). The mice were treated with vehicle, cisplatin, theanine, and TBrC by intraperitoneal injection once every day. The therapy was performed for 15 days. Tumor dimensions and mouse body weights were measured every 2 or 3 days by Vernier caliper. Tumor volume was calculated using the formula: tumor size (cm 3 ) = [width (cm)] 2 9 [length(cm)] 9 0.52 (Naumov et al. 2009 ). On the 15th day, mice in all groups were sacrificed. Tumor volumes and weights were compared among the groups using the ANOVA and Bonferroni test. All statistical tests were two-sided.
Statistical analysis
The data were expressed as mean ± standard deviation (SD) and analyzed by the SPSS 13.0 software to evaluate the statistical difference. Statistical analysis was done using the ANOVA and Bonferroni test. Values between different treatment groups at different times were compared. The rate (%) of relative cell growth and migration as well as mean protein levels are shown for each group. For all tests, P values\0.05 were considered statistically significant. All statistical tests were two-sided.
Results and discussion
TBrC enhances proliferation inhibition, induction of apoptosis and cell cycle arrest in LLC cells
We first compared the in vitro anticancer activity of TBrC with its parent compound theanine and the inhibitors of PI3K/Akt (Ly) and NF-jB (Bay), which have a similar function or signaling pathway in anticancer activity against the proliferation inhibition of highly-metastatic LLC cells. The MTT assay confirmed that TBrC increased the inhibition of LLC cell growth by 2-3 fold compared with theanine after the cells were treated with TBrC and theanine (16-250 lM) for 48 and 72 h, respectively (Fig. 2a) . In the same conditions, TBrC did not show significant inhibition of the growth of normal human umbilical vein endothelial cells (HUVECs) at concentrations of 16-125 lM although TBrC led to a weak growth inhibition of HUVECs at 250 lM (Fig. 2b) . The result indicated that there is no strong toxicity of TBrC on the growth of normal HUVECs. However, theanine led to growth inhibition of HUVECs at 64-250 lM (Fig. 2b) . Moreover, the inhibitor of PI3K/Akt (Ly, 16 lM) and NF-jB (Bay, 3.2 microM) remarkably inhibited the growth of both LLC (Fig. 2a) and normal HUVEC cells (Fig. 2b) . Furthermore, FACS analysis indicated that TBrC (16-250 lM) exhibited much stronger activity than theanine (16-250 lM) on induction of apoptosis and cell cycle arrest in LLC cells after the cells were treated for 48 h. The apoptotic ratio of LLC cells was 45.95 % in the treatment by TBrC (250 lM) while the apoptotic ratio of LLC cells was 4.62 % in the treatment with the same concentration of theanine (Fig. 2c) . The induction of the apoptosis in LLC cells by TBrC could greatly contribute to the proliferation inhibition of LLC cells (Fig. 2a) . In addition, the inhibitors of PI3K/Akt (Ly, 16 lM) and NF-jB (Bay, 3.2 lM) also induced the apoptosis in LLC cells. The apoptotic ratios of LLC cells were 17.92 and 39.27 %, respectively. TBrC has shown an activity comparable with Ly and Bay on induction of apoptosis in LLC cells.
TBrC enhances the migration inhibition in LLC cells
The presence of metastasis is the main cause of morbidity and mortality in millions of patients with cancer. During the complicated process of metastasis, the migration of cancer cells is the most important step. Clearly, an agent which could efficiently inhibit the growth and migration of cancer cells would be a hopeful candidate to suppress cancer progression and metastasis and thus could reduce mortality. Therefore, we examined the effects of TBrC and theanine on the migration in LLC cells. The migration assay indicated that TBrC (4-16 lM) and theanine (8-16 lM) significantly and dose-dependently suppressed the migration of LLC cells after the cells were treated for 6 h. TBrC displayed a much stronger inhibition than theanine against the migration of LLC cells (Fig. 3a, b) . The relative migration rate was reduced by 25-37 % and 10-20 %, respectively by 6 h treatment with TBrC and theanine at the concentrations of 4-16 lM, which did not significantly inhibit the LLC cell growth (data not shown).
TBrC enhances the down-regulation of the protein levels of Bcl-2 and cyclin D1 and increases the upregulation of the protein levels of Bax, cytosolic cytochrome c, caspase-3, and PARP-1 in LLC cells
To understand the molecular mechanisms of action of TBrC on the proliferation and induction of apoptosis and cell cycle arrest in LLC cells, we compared the effects of TBrC with theanine as well as Ly and Bay on the expressions of related protein. Our results showed that TBrC (16-250 lM) and theanine (16-250 lM) significantly reduced the Bcl-2 protein levels in LLC cells. TBrC displayed much stronger activity than theanine on the down-regulation of Bcl-2 protein expressions in LLC cells (Fig. 4a) . Furthermore, TBrC (16-250 lM) and theanine (16-250 lM) remarkably up-regulated the protein expressions of Bax (Fig. 4a) , cytosolic cytochrome c (Fig. 4b) , caspase-3 (Fig. 4c) , and the cleavage of poly(ADP-ribose) polymerase-1 (PARP-1) (Fig. 4d) in LLC cells. TBrC showed much stronger activity than theanine on the up-regulation of these protein expressions in LLC cells (Fig. 4a-d) . Moreover, TBrC (16-250 lM) and theanine (16-250 lM) significantly reduced the cyclin D1 protein expression in LLC cells. TBrC also exhibited much stronger activity than theanine on the down-regulation of cyclin D1 protein expressions in LLC cells (Fig. 4e) . In addition, the inhibitors of NF-jB (Bay) and PI3K/Akt (Ly) showed a significant suppression of the protein expressions of Bcl-2, and cyclin D1 and increase in the protein levels of Bax, cytosolic cytochrome c, caspase-3, and cleavage of PARP-1 in LLC cells (Fig. 4) . TBrC has shown a comparable activity with Ly and Bay on the regulation of protein expressions of cyclin D1, Bcl-2/Bax, cytosolic cytochrome c, caspase-3, and PARP-1 in LLC cells.
One of the main regulatory steps of apoptotic cell death is controlled by the ratio of antiapoptotic and proapoptotic members of the Bcl-2 family of proteins, which determines the susceptibility to apoptosis. Bax, a proapoptotic factor of the Bcl-2 family, is found in monomeric form in the cytosol or is loosely attached to the membranes under normal conditions. Following a death stimulus, cytosolic and monomeric Bax translocates to the mitochondria where it becomes an integral membrane protein and cross-linkable as a homodimer allowing for the release of factors from the mitochondria, such as cytochrome c, to propagate the apoptotic pathway (Oltvai et al. 1993 ). Bcl-2 and its related proteins control the release of cytochrome c from the mitochondria (Reed 1997) . Hallmarks of the apoptotic process include the activation of cysteine proteases, which represent both initiators and executors of cell death. In the cytosol, cytochrome c activates caspase-9, which in turn activates the effector caspase such as caspase-3 and caspase-7 (Stennicke and Salvesen 2000) . In the present study, we observed that TBrC significantly enhanced the down-regulation of the antiapoptotic Bcl-2 levels and up-regulation of proapoptotic Bax levels, leading to s reduction of Bcl-2/Bax ratio (Fig. 4a) . Furthermore, TBrC significantly enhanced the release of cytochrome c from mitochondria (Fig. 4b) and subsequently increased caspase-3 activity (Fig. 4c) . Caspase-3 is synthesized as a 35-kDa inactive precursor (procaspase-3), which is proteolytically cleaved to produce a mature enzyme composed of 17-kDa fragments. As shown in Fig. 4c , caspase-3 in cleaved form was enhanced with the b Fig. 2 increase in the concentrations of TBrC. In addition, we observed the up-regulation of cleavage of PARP-1, the substrate of caspase-3, in LLC cells treated with TBrC (Fig. 4d) . Moreover, our results also indicated that TBrC significantly enhanced the down-regulation of cyclin D1 protein expression in LLC cells (Fig. 4e) . Taken together, all these results indicated that TBrC significantly suppressed the proliferation of LLC cells and remarkably induced apoptosis and cell cycle arrest by reducing Bcl-2/Bax ratio and activating the mitochondrial and caspase-3 pathway as well as reducing the protein levels of cyclin D1, the cell cycle regulator in LLC cells.
TBrC enhances the down-regulation of the receptor phosphorylation and/or protein expressions of VEGFR1, VEGFR2, Akt and NF-jB in LLC cells
The activated receptors such as VEGFR1 and VEG-FR2 play very important roles in the proliferation and migration of cancer cells including lung cancer cells (Morelli et al. 2006; Naumov et al. 2009; Lee et al. 2010; Zhang et al. 2012a, b) . In order to clarify the TBrC-targeted receptors in LLC cells, we studied the effects of TBrC on the related receptor phosphorylation and expression in LLC cells. We have confirmed that TBrC significantly reduced the expression of VEGFR1 (Fig. 5a ) and the phosphorylation and expression of VEGFR2 (Fig. 5b) in LLC cells. TBrC showed a much stronger activity than theanine on reduction of the phosphorylation and/or expressions of the receptors in LLC cells. In addition, the inhibitors of PI3K/Akt (Ly) and NF-jB (Bay) also displayed inhibitory effects on the phosphorylation and/or expression of the receptors (Fig. 5a, b) in LLC cells. TBrC has exhibited an activity comparable with Ly and Bay on the down-regulation of the phosphorylation and/or expression of VEGFR1 and VEGFR2 in LLC cells.
The down-regulation of the receptor phosphorylation and protein expression in LLC cells by TBrC could greatly contribute to the suppression of their downstream targets and the receptors-mediated PI3K/ Akt as well as the related signaling pathways, and thus expressed as relative optical density (OD). The OD value of the band shown as mean ± SD is relative to that of the control (DMSO vehicle) designated as 100 %. Bay and Ly are the inhibitors of NF-jB and PI3K/Akt, respectively. For one experiment, three assays were carried out and only one set of gels is shown. Values with different letters (a-g) differ significantly (P \ 0.05) Cytotechnology (2014) 66:899-911 907 leads to the inhibition of the proliferation and migration in LLC cells. In order to further confirm the inhibitory effects of TBrC on the receptors-mediated signaling pathways related to the proliferation and migration of LLC cells, we investigated the effects of TBrC on the suppression of the phosphorylation and/or expression of Akt and NF-jB in LLC cells. Our results indicated that TBrC significantly reduced the phosphorylation and expression of Akt (Fig. 5c ) and the NF-jB (p65) expression (Fig. 5d ) in LLC cells. TBrC also showed a much stronger activity than theanine on reduction of the phosphorylation and/or expression of the Akt and NFjB proteins in LLC cells. In addition, the inhibitors of PI3K/Akt (Ly) and NF-jB (Bay) displayed a significant suppression of the phosphorylation and protein expression of Akt and the NF-jB (p65) expression in LLC cells, respectively (Fig. 5c, d) . TBrC has shown an activity comparable with Ly and Bay on the downregulation of the Akt phosphorylation and expression and NF-jB expression in LLC cells.
Akt is a cytosolic signal transduction protein kinase that plays an important role in cell survival pathways (West et al. 2002) . Induction of Akt activity is the band was normalized with respect to b-actin and is expressed as relative optical density (OD). The OD value of the band shown as mean ± SD is relative to that of the control (DMSO vehicle) designated as 100 %. Bay and Ly are the inhibitors of NF-jB and PI3K/Akt, respectively. For one experiment, 3 assays were carried out and only one set of gels is shown. Values with different letters (a-f) differ significantly (P \ 0.05) primarily dependent on the PI3K pathway. Akt can be activated by many forms of cellular stress, such as those observed under treatment with anticancer agents (West et al. 2002) . Once activated, Akt controls cellular functions such as apoptosis, cell cycle, gene transcription, and protein synthesis through the phosphorylation of downstream substrates such as NF-jB (West et al. 2002) . NF-jB is a nuclear transcription regulator with a specific motif for Bcl-2 transcription (Wang et al. 1996; Marsden et al. 2002) . Activation of p-Akt and the NF-jB/Bcl-2 pathway leads to inhibition of chemotherapy-induced apoptosis, which results in treatment resistance (Wang et al. 1996) . Our previous results confirmed that suppression of Akt and the NF-jB/Bcl-2 pathway by anticancer agents inhibited the growth and migration as well as induced apoptosis and cell cycle arrest in human lung cancer A549 cells and breast cancer MDA-MB-231 cells Wang et al. 2009; Yu et al. 2009; Jiang et al. 2010; Zhang et al. 2012a) . In the present study, we indicated that TBrC significantly enhanced the inhibition of the proliferation and migration of LLC cells and the PI3K/Akt and NF-jB pathway by suppressing the phosphorylation and expression of Akt and the NF-jB expression and activating the apoptotic pathway related to changes of Bcl-2/Bax ratio, mitochondrial cytochrome C and caspase-3 in LLC cells.
There have been reports showing that suppression of VEGFR1 and VEGFR2 led to the inhibition of cancer cell proliferation, migration and metastasis (Morelli et al. 2006; Naumov et al. 2009; Wang et al. 2009; Jiang et al. 2010; Charpidou et al. 2011; Liu et al. 2011; Pajares et al. 2012; Zhang et al. 2012a ).
Here we have confirmed that TBrC significantly enhanced the inhibition of the VEGFR1 and VEGFR2 receptors and their downstream targets such as Akt and NF-jB in LLC cells, which could contribute to the Values with different letters (a-c) differ significantly (P \ 0.05). All statistical tests were two-sided. *, P \ 0.05; **, P \ 0.01; and ***, P \ 0.001 Cytotechnology (2014) 66:899-911 909 inhibition of LLC cell proliferation and migration as well as the tumor growth in vivo.
TBrC enhances suppression of tumor growth in vivo
The animal experimental results indicated that TBrC time-dependently inhibited highly-metastatic LLC tumor growth and remarkably reduced the tumor volumes and weights in tumor-bearing mice. TBrC showed much stronger activity than theanine against LLC tumor growth in tumor-bearing mice. The relative inhibitory rates of the LLC tumor volumes (Fig. 6a, c) and weights ( Fig. 6b) increased by 63.6 and 61.6 % (in the case of TBrC treatment) and by 34.5 and 29.7 % (in the case of theanine treatment), respectively, after treatment with TBrC and theanine for 15 days. As a positive control, the anticancer drug cisplatin also showed significant inhibition of the LLC tumor growth in the tumor-bearing mice. TBrC has shown an activity comparable with cisplatin on the suppression of LLC tumor growth in the mice (Fig. 6a-c) . In addition, TBrC and theanine did not show obvious toxicity to the mice by the analyses of the mouse body weights during the experiment and the pathological dissection of the mice (date not shown).
It should be noted that the higher water solubility of theanine and the structure of coumarin-3-carboxylic acid could hamper the antitumor activity in vitro and in vivo. In order to enhance the anticancer activity of theanine and coumarin-3-carboxylic acid, we synthesized TBrC by acylation of the amino group with 6-substituted coumarin-3-carboxylic acid and esterification of the carboxyl group with ethanol. This structure of TBrC could greatly enhance the concentration and prolong the time of effective compounds in the cancer cells. This increases the anticancer activity in vitro and in vivo as we have observed in the present study. Theanine showed its significant and peak inhibition of cancer cell growth at 1 h after its oral intubation in rats as reported in our previous studies (Zhang et al. 2001; Liu et al. 2009 ). However, TBrC exhibits its significant inhibition of cancer cell growth for 8 h and the peak inhibition of cancer cell growth at 5 h after its oral intubation in rats in our experiments (data not shown).
In summary, our present results have demonstrated that TBrC significantly suppresses LLC cell proliferation and migration, and induces apoptosis and cell cycle arrest by targeting the VEGFR1 and VEGFR2 receptors-mediated signaling pathways of Akt and NF-jB in LLC cells. TBrC has not displayed any toxicity to the mice except for the strong suppression of the tumor growth in the tumor-bearing mice. All these findings suggest that TBrC as a new anticancer compound may have a wide therapeutic and/or adjuvant therapeutic application in the treatment of lung cancer.
